Food and Drug Administration leaders are signaling new flexibility in the agency’s approach to evaluating new therapies to help people stop smoking.
In a perspective paper published with the National Institutes of Health this week, the agency labeled the effort to help Americans quit smoking a top priority and said it was willing to consider broader endpoints in clinical trials of smoking cessation products.
The two health agencies will hold a public meeting on Monday to discuss their regulatory approach for smoking cessation therapies going forward.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
